Authors
Loading...
Molecular docking reveals effective anticancer candidates targeting EGFR, suggesting robust drug properties.
Kaur et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: